FDA to Stem Cell Clinics: File an IND by June 1, or Close Business 

For several years, stem cell clinics in the US have flourished offering treatments to patients for all kinds of ailments, despite the FDA warning that these treatments are illegal under the US regulations. That ends on 1st June 2021 when FDA will finally initiate aggressive enforcement actions against such clinics, announced FDA’s Director for the … Read more

FDA Starts Enforcing Clinicaltrial.gov Law 

Almost 14 years since the passage of the law requiring that results of clinical trials be posted within a year of trial completion, yesterday, FDA issued the first notice of non-compliance to a sponsor for violating the law, and promised stricter enforcement going forward. Ever since the creation of the clinicaltrials.gov online registry in the … Read more

FDA To Limit Interstate Distribution of Compounded Drugs 

Compounding pharmacies will be limited to distributing less than 5% of their compounded drugs out of the state in which they are physically located starting 27 October 2021. Many compounding pharmacies ship more than 50% of their compounded drugs out of state meaning these pharmacies will lose bulk of their business owing to the new … Read more

Emergent’s FDA Audit Indicates Poor Vendor Validation by J & J

Yesterday FDA published the FDA 483 for Emergent’s vaccine manufacturing facility in Baltimore listing a litany of non-compliance findings made by its inspectors, and it points to the abysmal job done by J&J’s vendor validation team. Prior to giving a contract to a vendor it is essential that the client company conduct a thorough review … Read more

Its Time To Restart Clinical Trials in the US 

With wider vaccination and easing of mobility restrictions in the US, this is the time to restart clinical trials suspended or postponed last year due to the pandemic. But it may not be as simple; there are five areas of consideration for clinical trial restart. First, availability of human resources is still not at the … Read more

Are FDA’s In-Person Meetings Coming Back in the Fall?

One of the casualties of the pandemic last year was the in-person meetings with FDA reviewers. For obvious reasons, FDA converted all its meetings since March 2020 to the virtual or phone call format as an alternate to in-person meetings on the FDA campus. Now, as the pandemic slowly winds down in the US, would … Read more

Do FDA’s Procedures Make it Easier to Cover-up Negative Audit Findings?

We often hear the manufacturer’s side of the FDA audit experience but not what happens internally at the FDA. A recently concluded investigation of a disagreement between an FDA inspector and his manager regarding his reports of non-compliance at manufacturing facilities by the Office of the Special Counsel provides a unique insight into FDA’s internal … Read more